

Table I. *Patient characteristics.*

Characteristic	N (%)
Gender	
Male	222 (76.8)
Female	67 (23.2)
Age (years old)	
Mean (range)	71 (43-91)
Clinical stage	
Stage 0	1 (0.3)
Stage I	97 (33.6)
Stage II	31 (10.7)
Stage III	48 (16.6)
Stage IV	112 (38.8)
Proximal tumor location	
Ce	47 (16.3)
Ut	85 (29.4)
Mt	130 (50.0)
Lt	25 (8.7)
Ae	2 (0.7)
Distal tumor location	
Ce	21 (7.3)
Ut	41 (14.2)
Mt	109 (37.7)
Lt	99 (34.3)
Ae	19 (6.6)
Histology	
Squamous cell carcinoma	281 (97.2)
Adenocarcinoma	6 (2.1)
Others	2 (0.7)
Irradiation technique	
3D-CRT	209 (72.3)
VMAT	80 (27.7)
Performance status	
0	149 (51.6)
1	105 (36.3)
2	21 (7.3)
3	6 (2.1)
4	2 (0.7)
Unknown	6 (2.1)
Induction chemotherapy	
Yes	2 (0.7)
No	279 (99.3)
Concurrent chemotherapy	
Yes	170 (58.8)
No	119 (41.2)
Adjuvant chemotherapy	
Yes	108 (37.4)
No	181 (62.6)
Hemoglobin level (g/dl)	
Mean (range)	12.8 (7.4-17.5)
Serum albumin level (g/dl)	
Mean (range)	4 (1.5-5)
Median follow-up (months)	18 (2-98)

Ce: Cervical esophagus; Ut: upper thoracic esophagus; Mt: middle thoracic esophagus; Lt: lower thoracic esophagus; Ae: abdominal esophagus; VMAT: volumetric modulated arc therapy; 3D-CRT: three-dimensional conformal radiation therapy.